Medicinal chemistry of adenosine, P2Y and P2X receptors

[1]  Dr. Wim Huppes,et al.  Clinical Evaluation , 2021, Oxford Textbook of Endocrinology and Diabetes 3e.

[2]  K. Fuxe,et al.  Purinergic signaling in Parkinson's disease. Relevance for treatment , 2016, Neuropharmacology.

[3]  Leigh A. Stoddart,et al.  Probing the pharmacology of G protein-coupled receptors with fluorescent ligands , 2015, Neuropharmacology.

[4]  Kyle A. Brown,et al.  Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor. , 2015, Bioorganic & medicinal chemistry letters.

[5]  P. Bonaventure,et al.  A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. , 2015, European journal of pharmacology.

[6]  P. Bonaventure,et al.  Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. , 2015, Bioorganic & medicinal chemistry letters.

[7]  C. Normann,et al.  Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a , 2015, Neuron.

[8]  R. Stevens,et al.  Nucleotides Acting at P2Y Receptors: Connecting Structure and Function , 2015, Molecular Pharmacology.

[9]  C. Müller,et al.  α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. , 2015, Journal of medicinal chemistry.

[10]  Qiang Zhao,et al.  Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information , 2015, Journal of Computer-Aided Molecular Design.

[11]  K. Jacobson,et al.  Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. , 2015, Bioorganic & medicinal chemistry.

[12]  A. Schiedel,et al.  Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors , 2015, Purinergic Signalling.

[13]  K. Jacobson,et al.  Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain , 2015, Purinergic Signalling.

[14]  N. Volkow,et al.  Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer , 2015, Proceedings of the National Academy of Sciences.

[15]  A. Leslie,et al.  Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor , 2015, Molecular Pharmacology.

[16]  G. Hutchins,et al.  Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor. , 2015, Bioorganic & medicinal chemistry letters.

[17]  D. Kawano,et al.  Insights into Ecto-5'-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study. , 2015, Current medicinal chemistry.

[18]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[19]  P. Séguéla,et al.  Identification and Characterization of a Selective Allosteric Antagonist of Human P2X4 Receptor Channels , 2015, Molecular Pharmacology.

[20]  Hualiang Jiang,et al.  Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.

[21]  G. Schmalzing,et al.  Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis , 2015, Current medicinal chemistry.

[22]  C. Müller.  Medicinal chemistry of P2X receptors: allosteric modulators. , 2015, Current medicinal chemistry.

[23]  F. Virgilio.  P2X receptors and inflammation. , 2015 .

[24]  E. Fabbretti,et al.  P2X receptors, sensory neurons and pain. , 2015, Current medicinal chemistry.

[25]  G. Burnstock.  Physiopathological roles of P2X receptors in the central nervous system. , 2015, Current medicinal chemistry.

[26]  G. Marucci,et al.  Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists. , 2015, Current medicinal chemistry.

[27]  Alina Ghinet,et al.  Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. , 2015, Current medicinal chemistry.

[28]  C. Müller,et al.  Polyoxometalates--potent and selective ecto-nucleotidase inhibitors. , 2015, Biochemical pharmacology.

[29]  G. Marucci,et al.  Purinergic P2X receptors: structural models and analysis of ligand-target interaction. , 2015, European journal of medicinal chemistry.

[30]  G. Ellis‐Davies,et al.  Caged compounds for multichromic optical interrogation of neural systems , 2015, The European journal of neuroscience.

[31]  P. Bonaventure,et al.  Pharmacology of a Novel Central Nervous System–Penetrant P2X7 Antagonist JNJ-42253432 , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[32]  I. Baranowska-Bosiacka,et al.  P2X and P2Y Receptors—Role in the Pathophysiology of the Nervous System , 2014, International journal of molecular sciences.

[33]  R. Schmid,et al.  Use of Chimeras, Point Mutants, and Molecular Modeling to Map the Antagonist-binding Site of 4,4′,4″,4‴-(Carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic Acid (NF449) at P2X1 Receptors for ATP* , 2014, The Journal of Biological Chemistry.

[34]  Steven M. Moss,et al.  In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of C2-Arylethynyl Group of Conformationally Constrained A3 Adenosine Receptor Agonists , 2014, Journal of medicinal chemistry.

[35]  C. Müller,et al.  Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1). , 2014, Journal of medicinal chemistry.

[36]  Marco Foddis,et al.  Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model , 2014, Nature Communications.

[37]  C. Müller,et al.  Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12‐receptor , 2014, Journal of thrombosis and haemostasis : JTH.

[38]  S. Ward,et al.  Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut , 2014, Proceedings of the National Academy of Sciences.

[39]  M. Young,et al.  Purinergic P2X receptors: structural and functional features depicted by X-ray and molecular modelling studies. , 2014, Current medicinal chemistry.

[40]  Kyle A. Brown,et al.  Exploring a 2-Naphthoic Acid Template for the Structure-Based Design of P2Y14 Receptor Antagonist Molecular Probes , 2014, ACS chemical biology.

[41]  B. Sperlágh,et al.  Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents , 2014, Neurobiology of Disease.

[42]  G. Reiser,et al.  5-OMe-uridine-5′-O-(α-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y6 receptor protects against death-receptor mediated glial apoptosis , 2014, Neuroscience Letters.

[43]  J. Iqbal,et al.  Therapeutic Potentials of Ecto‐Nucleoside Triphosphate Diphosphohydrolase, Ecto‐Nucleotide Pyrophosphatase/Phosphodiesterase, Ecto‐5′‐Nucleotidase, and Alkaline Phosphatase Inhibitors , 2014, Medicinal research reviews.

[44]  K. Jacobson,et al.  Potential for Developing Purinergic Drugs for Gastrointestinal Diseases , 2014, Inflammatory bowel diseases.

[45]  L. Stokes,et al.  The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease , 2014, Pharmacological Reviews.

[46]  C. Müller,et al.  BAY60-6583 Acts as a Partial Agonist at Adenosine A2B Receptors , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[47]  K. Varani,et al.  TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice , 2014, Neuropharmacology.

[48]  Hualiang Jiang,et al.  Agonist-bound structure of the human P2Y12 receptor , 2014, Nature.

[49]  M. Díaz-Ríos,et al.  Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. , 2014, Life sciences.

[50]  Kenneth A. Jacobson,et al.  4-Alkyloxyimino Derivatives of Uridine-5′-triphosphate: Distal Modification of Potent Agonists as a Strategy for Molecular Probes of P2Y2, P2Y4, and P2Y6 Receptors , 2014, Journal of medicinal chemistry.

[51]  Shane M. Wilkinson,et al.  The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. , 2014, ACS chemical neuroscience.

[52]  Martin J. Lohse,et al.  G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives , 2014, Pharmacological Reviews.

[53]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[54]  C. Müller,et al.  Carbamazepine derivatives with P2X4 receptor-blocking activity. , 2014, Bioorganic & medicinal chemistry.

[55]  Damien Lemoine,et al.  Exploring the ATP-binding site of P2X receptors , 2013, Front. Cell. Neurosci..

[56]  A. Ford,et al.  The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders , 2013, Front. Cell. Neurosci..

[57]  P. Séguéla,et al.  Post-translational regulation of P2X receptor channels: modulation by phospholipids , 2013, Front. Cell. Neurosci..

[58]  P. Bonaventure,et al.  Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567 , 2013, British journal of pharmacology.

[59]  G. Reiser,et al.  Sp-2-propylthio-ATP-α-B and Sp-2-propylthio-ATP-α-B,β-γ-dichloromethylene are novel potent and specific agonists of the human P2Y₁₁ receptor. , 2013, Biochemical pharmacology.

[60]  E. Audinat,et al.  Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus , 2013, Glia.

[61]  M. Hediger,et al.  Investigation of the Inhibitory Effects of the Benzodiazepine Derivative, 5-BDBD on P2X4 Purinergic Receptors by two Complementary Methods , 2013, Cellular Physiology and Biochemistry.

[62]  Silvia Paoletta,et al.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. , 2013, Journal of medicinal chemistry.

[63]  K. Jacobson,et al.  A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose–Stimulated Chemotaxis of Human Neutrophils , 2013, Molecular Pharmacology.

[64]  F. Di Virgilio,et al.  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[65]  B. Fredholm,et al.  Adenosine receptors as drug targets — what are the challenges? , 2013, Nature Reviews Drug Discovery.

[66]  P. Bonaventure,et al.  Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists. , 2013, ACS medicinal chemistry letters.

[67]  C. Müller,et al.  The platelet P2Y12 receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [3H]PSB-0413 , 2013, Purinergic Signalling.

[68]  J. Y. Roberge,et al.  Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. , 2013, Journal of medicinal chemistry.

[69]  S. Ceruti,et al.  P2Y purinergic receptors: new targets for analgesic and antimigraine drugs. , 2013, Biochemical pharmacology.

[70]  R. Petrelli,et al.  5'-Chloro-5'-deoxy-(±)-ENBA, a Potent and Selective Adenosine A1 Receptor Agonist, Alleviates Neuropathic Pain in Mice Through Functional Glial and Microglial Changes without Affecting Motor or Cardiovascular Functions , 2012, Molecules.

[71]  C. Müller,et al.  N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. , 2012, Journal of medicinal chemistry.

[72]  S. Metcalfe.  Life and times. , 2012, Australian family physician.

[73]  Steven M. Moss,et al.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. , 2012, Journal of medicinal chemistry.

[74]  E. Keystone,et al.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine , 2012, Annals of the rheumatic diseases.

[75]  M. Schaefer,et al.  Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors , 2012, British journal of pharmacology.

[76]  Younis Baqi,et al.  Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. , 2012, Pharmacology & therapeutics.

[77]  G. Schmalzing,et al.  P2X1 and P2X2 receptors in the central nervous system as possible drug targets. , 2012, CNS & neurological disorders drug targets.

[78]  G. Weisman,et al.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential. , 2012, CNS & neurological disorders drug targets.

[79]  S. Beggs,et al.  P2X4R+ microglia drive neuropathic pain , 2012, Nature Neuroscience.

[80]  Joseph E. Rittiner,et al.  Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice. , 2012, Journal of medicinal chemistry.

[81]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[82]  G. Burnstock,et al.  Purinergic Signalling and the Nervous System , 2012, Springer Berlin Heidelberg.

[83]  K. Jacobson,et al.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.

[84]  N. Sträter,et al.  Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.

[85]  M. Hattori,et al.  Molecular mechanism of ATP binding and ion channel activation in P2X receptors , 2012, Nature.

[86]  K. Jacobson,et al.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists. , 2012, Drug discovery today.

[87]  C. Mebus,et al.  Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate , 2012, The Journal of Rheumatology.

[88]  Y. de Koninck,et al.  P2X4 Receptors Influence Inflammasome Activation after Spinal Cord Injury , 2012, The Journal of Neuroscience.

[89]  P. Ponikowski,et al.  The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina , 2012, Clinical Research in Cardiology.

[90]  J. Jankowski,et al.  Uridine adenosine tetraphosphate (Up4A) is a strong inductor of smooth muscle cell migration via activation of the P2Y2 receptor and cross-communication to the PDGF receptor. , 2012, Biochemical and biophysical research communications.

[91]  J. Camden,et al.  Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues. , 2012, Journal of medicinal chemistry.

[92]  S. El-Ajouz,et al.  Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop , 2012, British journal of pharmacology.

[93]  J. Lanciego,et al.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. , 2011, Pharmacology & therapeutics.

[94]  A. Ford.  In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization , 2011, Purinergic Signalling.

[95]  Kenneth A Jacobson,et al.  Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. , 2011, Biochemical pharmacology.

[96]  Stanko S. Stojilkovic,et al.  Activation and Regulation of Purinergic P2X Receptor Channels , 2011, Pharmacological Reviews.

[97]  C. Gachet,et al.  P2 receptors and platelet function , 2011, Purinergic Signalling.

[98]  Yongxin Han,et al.  Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14). , 2011, Bioorganic & medicinal chemistry letters.

[99]  A. Kalgutkar,et al.  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. , 2011, Bioorganic & medicinal chemistry letters.

[100]  C. Coddou,et al.  Allosteric modulation of ATP-gated P2X receptor channels , 2011, Reviews in the neurosciences.

[101]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[102]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[103]  Letisha R. Wyatt,et al.  Ethanol Is a Fast Channel Inhibitor of P2X4 Receptors , 2011, Journal of Pharmacology and Experimental Therapeutics.

[104]  M. Zylka,et al.  Pain-relieving prospects for adenosine receptors and ectonucleotidases. , 2011, Trends in molecular medicine.

[105]  G. Bahrenberg,et al.  Molecular Determinants of Potent P2X2 Antagonism Identified by Functional Analysis, Mutagenesis, and Homology Docking , 2011, Molecular Pharmacology.

[106]  C. Müller,et al.  Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. , 2011, Journal of medicinal chemistry.

[107]  J. Gever,et al.  AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist , 2010, British journal of pharmacology.

[108]  Wei Liu,et al.  Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture , 2010, Nature Neuroscience.

[109]  P. Sokoloff,et al.  Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. , 2010, Sleep.

[110]  C. Müller.  Emerging structures and ligands for P2X3 and P2X4 receptors—towards novel treatments of neuropathic pain , 2010, Purinergic Signalling.

[111]  North Ra,et al.  Amitriptyline does not block the action of ATP at human P2X4 receptor , 2010, British journal of pharmacology.

[112]  M. Kassiou,et al.  P2X purinergic receptor ligands: recently patented compounds , 2010, Expert opinion on therapeutic patents.

[113]  B. Sperlágh,et al.  A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain , 2010, British journal of pharmacology.

[114]  G. Schmalzing,et al.  NF546 [4,4′-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-α,α′-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y11 Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[115]  K. Jacobson,et al.  Quantification of Gi-Mediated Inhibition of Adenylyl Cyclase Activity Reveals That UDP Is a Potent Agonist of the Human P2Y14 Receptor , 2009, Molecular Pharmacology.

[116]  S. Maier,et al.  Enduring Reversal of Neuropathic Pain by a Single Intrathecal Injection of Adenosine 2A Receptor Agonists: A Novel Therapy for Neuropathic Pain , 2009, The Journal of Neuroscience.

[117]  H. Mischak,et al.  Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system , 2009, British journal of pharmacology.

[118]  M. Kassiou,et al.  Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. , 2009, Bioorganic & medicinal chemistry.

[119]  M. Mattson,et al.  Amyloid-β Induces a Caspase-mediated Cleavage of P2X4 to Promote Purinotoxicity , 2009, NeuroMolecular Medicine.

[120]  E. Gouaux,et al.  Crystal structure of the ATP-gated P2X4 ion channel in the closed state , 2009, Nature.

[121]  Thomas Borrmann,et al.  1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. , 2009, Journal of medicinal chemistry.

[122]  R. Stewart,et al.  Conserved extracellular cysteines differentially regulate the inhibitory effect of ethanol in rat P2X4 receptors. , 2009, Biochemical and biophysical research communications.

[123]  K. Klotz,et al.  N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. , 2009, Journal of medicinal chemistry.

[124]  J. Gever,et al.  Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. , 2009, Bioorganic & medicinal chemistry letters.

[125]  J. Gever,et al.  Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. , 2009, Bioorganic & medicinal chemistry letters.

[126]  P. Séguéla,et al.  Subtype-specific regulation of P2X3 and P2X2/3 receptors by phosphoinositides in peripheral nociceptors , 2009, Molecular pain.

[127]  H. Tozaki-Saitoh,et al.  Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief , 2009, Molecular pain.

[128]  P. Séguéla,et al.  Phosphoinositides Regulate P2X4 ATP-Gated Channels through Direct Interactions , 2008, The Journal of Neuroscience.

[129]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[130]  E. Elzein,et al.  A1 adenosine receptor agonists and their potential therapeutic applications , 2008 .

[131]  P. Séguéla,et al.  Direct Modulation of P2X1 Receptor-Channels by the Lipid Phosphatidylinositol 4,5-Bisphosphate , 2008, Molecular Pharmacology.

[132]  K. Jacobson,et al.  Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation. , 2008, Biochemical pharmacology.

[133]  D. Donnelly-roberts,et al.  Painful Purinergic Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[134]  P. Leeson,et al.  From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. , 2007, Bioorganic & medicinal chemistry letters.

[135]  F. Di Virgilio,et al.  Liaisons dangereuses: P2X(7) and the inflammasome. , 2007, Trends in pharmacological sciences.

[136]  Yong‐Chul Kim,et al.  Structure−Activity Relationship Studies of Spinorphin as a Potent and Selective Human P2X3 Receptor Antagonist , 2007 .

[137]  A. Verkhratsky,et al.  Ivermectin potentiates ATP-induced ion currents in cortical neurones: Evidence for functional expression of P2X4 receptors? , 2007, Neuroscience Letters.

[138]  K. Jacobson,et al.  UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis , 2007, Nature.

[139]  K. Klotz,et al.  [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.

[140]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[141]  S. Summerfield,et al.  Investigation into the role of P2X3/P2X2/3 receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological study , 2006, British journal of pharmacology.

[142]  J. Gever,et al.  Pharmacology of P2X channels , 2006, Pflügers Archiv.

[143]  J. Gever,et al.  Purinoceptors as therapeutic targets for lower urinary tract dysfunction , 2006, British journal of pharmacology.

[144]  C. Müller,et al.  P2 receptors activated by uracil nucleotides--an update. , 2006, Current medicinal chemistry.

[145]  H. Ulrich,et al.  Inhibition mechanism of the recombinant rat P2X(2) receptor in glial cells by suramin and TNP-ATP. , 2006, Biochemistry.

[146]  Z. Ge,et al.  Adenosine Inhibits Tumor Necrosis Factor-α Release from Mouse Peritoneal Macrophages via A2A and A2B but Not the A3 Adenosine Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[147]  D. Cockayne,et al.  P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP , 2005, The Journal of physiology.

[148]  J. Gever,et al.  Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist. , 2005, Bioorganic & medicinal chemistry letters.

[149]  J. DeJongh,et al.  Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. , 2005, European journal of pharmacology.

[150]  J. Boyer,et al.  Structure–activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors , 2005, Purinergic Signalling.

[151]  H. Schlüter,et al.  Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor , 2005, Nature Medicine.

[152]  S. Ōmura,et al.  The life and times of ivermectin — a success story , 2004, Nature Reviews Microbiology.

[153]  K. Jacobson,et al.  Induction of Novel Agonist Selectivity for the ADP-Activated P2Y1 Receptor Versus the ADP-Activated P2Y12 and P2Y13 Receptors by Conformational Constraint of an ADP Analog , 2004, Journal of Pharmacology and Experimental Therapeutics.

[154]  K. Jacobson,et al.  2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. , 2004, Biochemical pharmacology.

[155]  P. Kemp,et al.  Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. , 2004, American journal of respiratory cell and molecular biology.

[156]  G. Burnstock,et al.  Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane‐anaesthetized rats , 2004, British journal of pharmacology.

[157]  K. Jacobson,et al.  Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. , 2004, Biochemical pharmacology.

[158]  M. Kassack,et al.  Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. , 2004, European journal of medicinal chemistry.

[159]  R. Nicholas,et al.  Agonist Versus Antagonist Action of ATP at the P2Y4 Receptor Is Determined by the Second Extracellular Loop* , 2004, Journal of Biological Chemistry.

[160]  G. L. Waldo,et al.  Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. , 2004, Molecular pharmacology.

[161]  M. Roo,et al.  Dehydroepiandrosterone Potentiates Native Ionotropic ATP Receptors Containing the P2X2 Subunit in Rat Sensory Neurones , 2003, The Journal of physiology.

[162]  S. Koizumi,et al.  P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury , 2003, Nature.

[163]  M. Jarvis.  Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain , 2003, Expert opinion on therapeutic targets.

[164]  H. Schlüter,et al.  Identification of dinucleoside polyphosphates in adrenal glands. , 2003, Biochemical and biophysical research communications.

[165]  P. Illés,et al.  Stimulation of P2Y1 Receptors Causes Anxiolytic-like Effects in the Rat Elevated Plus-maze: Implications for the Involvement of P2Y1 Receptor-Mediated Nitric Oxide Production , 2003, Neuropsychopharmacology.

[166]  D. Erlinge,et al.  The stable pyrimidines UDPbetaS and UTPgammaS discriminate between contractile cerebrovascular P2 receptors. , 2003, European journal of pharmacology.

[167]  T. Brennan,et al.  A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[168]  ジーン カトラー,et al.  G-protein coupled receptor , 2001 .

[169]  A. Gomtsyan,et al.  ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. , 2000, The Journal of pharmacology and experimental therapeutics.

[170]  G. Schmalzing,et al.  The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor , 2000, Neuropharmacology.

[171]  R. Nicholas,et al.  ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. , 2000, Molecular pharmacology.

[172]  J. Chambers,et al.  A G Protein-coupled Receptor for UDP-glucose* , 2000, The Journal of Biological Chemistry.

[173]  J. Brown,et al.  Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors , 2000, Nature.

[174]  E A Kowaluk,et al.  Allosteric modulation and accelerated resensitization of human P2X(3) receptors by cibacron blue. , 1999, The Journal of pharmacology and experimental therapeutics.

[175]  W. Stühmer,et al.  Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors , 1999, Neuropharmacology.

[176]  K. J. Miller,et al.  Cibacron blue allosterically modulates the rat P2X4 receptor , 1998, Neuropharmacology.

[177]  G. Spalluto,et al.  A2A-adenosine receptor reserve for coronary vasodilation. , 1998, Circulation.

[178]  S. Moro,et al.  Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. , 1998, Journal of medicinal chemistry.

[179]  G. Burnstock,et al.  A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. , 1998, Journal of medicinal chemistry.

[180]  A. Nicke,et al.  P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand‐gated ion channels , 1998, The EMBO journal.

[181]  T. K. Harden,et al.  Identification of competitive antagonists of the P2Y1 receptor. , 1996, Molecular pharmacology.

[182]  W. Watt,et al.  Pharmacological selectivity of the cloned human P2U‐purinoceptor: potent activation by diadenosine tetraphosphate , 1995, British journal of pharmacology.

[183]  K. Jacobson,et al.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[184]  K. Jacobson,et al.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. , 1989, Journal of medicinal chemistry.

[185]  K. Jacobson,et al.  Pharmacological and Therapeutic Effects of A 3 Adenosine Receptor ( A 3 AR ) Agonists , 2017 .

[186]  K. Jacobson,et al.  Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. , 2015, Brain : a journal of neurology.

[187]  Y. Baqi,et al.  Ecto-nucleotidase inhibitors: recent developments in drug discovery. , 2015, Mini reviews in medicinal chemistry.

[188]  M. Congreve,et al.  Engineering G Protein-Coupled Receptors for Drug Design , 2015 .

[189]  H. Bölcskei,et al.  P2X3 and P2X2/3 receptor antagonists. , 2014, Pharmaceutical patent analyst.

[190]  M. Jindřichová,et al.  Allosteric modulation of ligand gated ion channels by ivermectin. , 2014, Physiological research.

[191]  Manjinder Singh,et al.  Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy. , 2014, Bioorganic & medicinal chemistry.

[192]  A. Bhattacharya,et al.  P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. , 2014, Progress in medicinal chemistry.

[193]  Jiang-fan Chen.  Adenosine receptor control of cognition in normal and disease. , 2014, International review of neurobiology.

[194]  S. Moro,et al.  Fluorescent ligands for adenosine receptors. , 2013, Bioorganic & medicinal chemistry letters.

[195]  Melinda K. Kutzing,et al.  Antagonism of purinergic signalling improves recovery from traumatic brain injury. , 2013, Brain : a journal of neurology.

[196]  R. Stevens,et al.  Fei Xu Adenosine Receptor 2 AStructure of an Agonist-Bound Human A , 2012 .

[197]  G. Reiser,et al.  Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. , 2008, The Biochemical journal.